This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2013 Apr;20(2):182-4.

doi: 10.1007/s12350-012-9658-y.

Use of regadenoson in end-stage renal disease

Ami E Iskandrian, Fadi G Hage, Jaekyeong Heo

PMID: 23225540
DOI: 10.1007/s12350-012-9658-y

Editorial

Use of regadenoson in end-stage renal disease

Ami E Iskandrian et al. J Nucl Cardiol. 2013 Apr.

. 2013 Apr;20(2):182-4.

doi: 10.1007/s12350-012-9658-y.

Authors

Ami E Iskandrian, Fadi G Hage, Jaekyeong Heo

PMID: 23225540
DOI: 10.1007/s12350-012-9658-y

No abstract available

PubMed Disclaimer

Comment on

The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. Doukky R, et al. J Nucl Cardiol. 2013 Apr;20(2):205-13. doi: 10.1007/s12350-012-9654-2. Epub 2012 Dec 13. J Nucl Cardiol. 2013. PMID: 23239416

Similar articles

The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
Doukky R, Rangel MO, Wassouf M, Dick R, Alqaid A, Morales Demori R. Doukky R, et al. J Nucl Cardiol. 2013 Apr;20(2):205-13. doi: 10.1007/s12350-012-9654-2. Epub 2012 Dec 13. J Nucl Cardiol. 2013. PMID: 23239416
The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
Doukky R, Fughhi I, Campagnoli T, Wassouf M, Ali A. Doukky R, et al. J Nucl Cardiol. 2017 Feb;24(1):112-118. doi: 10.1007/s12350-015-0303-4. Epub 2015 Nov 18. J Nucl Cardiol. 2017. PMID: 26582040
The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exercise for myocardial perfusion imaging using a SPECT protocol.
Thomas GS, Cullom SJ, Kitt TM, Feaheny KM, Ananthasubramaniam K, Gropler RJ, Jain D, Thompson RC. Thomas GS, et al. J Nucl Cardiol. 2017 Jun;24(3):788-802. doi: 10.1007/s12350-017-0813-3. Epub 2017 Feb 21. J Nucl Cardiol. 2017. PMID: 28224449 Free PMC article. Clinical Trial.
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.
Vij A, Golzar Y, Doukky R. Vij A, et al. J Nucl Cardiol. 2018 Feb;25(1):137-149. doi: 10.1007/s12350-017-0960-6. Epub 2017 Jun 26. J Nucl Cardiol. 2018. PMID: 28653271 Review.
Regadenoson: a focused update.
Ghimire G, Hage FG, Heo J, Iskandrian AE. Ghimire G, et al. J Nucl Cardiol. 2013 Apr;20(2):284-8. doi: 10.1007/s12350-012-9661-3. J Nucl Cardiol. 2013. PMID: 23229649 Review.

See all similar articles

Cited by

Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.
Salgado Garcia C, Jimenez Heffernan A, Sanchez de Mora E, Ramos Font C, Lopez Martin J, Rivera de los Santos F, Ynfante Milá I. Salgado Garcia C, et al. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):119-25. doi: 10.1007/s00259-013-2493-9. Epub 2013 Jul 16. Eur J Nucl Med Mol Imaging. 2014. PMID: 23857459

References

1. Circ Cardiovasc Imaging. 2009 Nov;2(6):429-36 - PubMed
1. J Nucl Cardiol. 2013 Apr;20(2):205-13 - PubMed
1. J Nucl Cardiol. 2012 Feb;19(1):126-41 - PubMed
1. Am J Cardiol. 2008 Dec 1;102(11):1451-6 - PubMed
1. Am J Cardiol. 2007 Sep 15;100(6):1020-5 - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Springer
Medical
- MedlinePlus Health Information